Rash Occurrence in Immune Thrombocytopenic Purpura (ITP)

Clinical Presentation of ITP

• ITP is characterized by low platelet counts resulting from platelet destruction and impaired platelet production, with an incidence of 2 to 5 per 100,000 people 1
• The primary skin manifestations in ITP are bleeding-related phenomena rather than inflammatory rashes, including petechiae and purpura 2

Frequency of Bleeding Manifestations

• Bleeding events in ITP are often unpredictable, and some patients with ITP, even with severe thrombocytopenia, may not exhibit bleeding beyond bruising and petechiae 1
• Severe bleeding is reported in 9.5% of adults and 20.2% of children with ITP 1
• Intracranial hemorrhage (ICH) is rare, reported in 1.4% of adults and 0.1% to 0.4% of children 1

Drug-Related Rashes in ITP Treatment

• Dapsone can cause severe skin rash that may require discontinuation of the drug 3
• Rituximab may cause infusion-related rash or scratchiness in the throat 3
• Danazol can cause acne in some patients 3

Clinical Pitfalls and Considerations

• The absence of skin manifestations does not rule out ITP, as some patients may be asymptomatic despite severe thrombocytopenia 1
• When evaluating a patient with suspected ITP, examination of the peripheral blood smear is essential to confirm the diagnosis and rule out other causes of thrombocytopenia 5
• The presence of additional features such as abnormal red or white blood cell morphology should raise suspicion for alternative diagnoses 5